Nuveen Asset Management, LLC Acelrx Pharmaceuticals Inc Transaction History

Nuveen Asset Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$1.03 - $1.7 $396,694 - $654,738	-385,140 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$1.25 - $2.77 $27,143 - $60,150	21,715 Added 5.98%	385,140 $655,000
Q4 2020 Feb 16, 2021	BUY	$1.18 - $1.98 $2,076 - $3,484	1,760 Added 0.49%	363,425 $451,000
Q3 2020 Nov 16, 2020	BUY	$1.01 - $1.81 $54,765 - $98,143	54,223 Added 17.64%	361,665 $514,000
Q2 2020 Aug 14, 2020	SELL	$1.03 - $1.69 $117,037 - $192,033	-113,629 Reduced 26.99%	307,442 $372,000
Q1 2020 May 14, 2020	SELL	$0.76 - $2.07 $98 - $267	-129 Reduced 0.03%	421,071 $496,000
Q4 2019 Feb 14, 2020	BUY	$1.66 - $2.4 $365,218 - $528,026	220,011 Added 109.36%	421,200 $889,000
Q2 2019 Aug 15, 2019	BUY	$2.1 - $3.93 $422,496 - $790,672	201,189 New	201,189 $509,000

Ticker ACRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 7,366,600
Market Cap $8.32M
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.